Anti-Bcl-9 (B-cell CLL/Lymphoma 9, MGC131591)

Bcl-9 (B-cell lymphoma 9, also Protein legless homolog) is a 149kD transcriptional regulator that belongs to the Bcl-9 family of proteins. It is expressed in multiple tissues and serves to recruit Pygopus to the Wnt-pathway beta-catenin-TCF complex in the nucleus. Bcl-9 and Bcl-9-2 are considered evolutionary duplicates of Legless that perform the same task with different regulatory mechanisms. Human Bcl-9 is 1426aa in length. It contains one phosphothreonine and three phosphoserine sites, two poly-Pro regions (aa514-517 and 970-973), and one , poly-Ala segment (aa900-903). There is one potential alternate start site at Met27, and a variant isoform exists that shows a four aa substitution for aa 1391-1426. Over aa1009-1328, human Bcl-9 is 96% aa identical to mouse Bcl-9. B cell cancers often have translocations at the 3'UTR , region of the Bcl-9 gene. , , Applications: , Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 0.5ug/ml, Optimal dilutions to be determined by the researcher. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.